Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...175176177178179180181182183184185...208209»
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia ?SAA? Patient (clinicaltrials.gov) -  Apr 29, 2020   
    P2,  N=55, Recruiting, 
    Research Funding: Jiangsu Hengrui Medicine Co., Ltd Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P2 | Trial completion date: Jun 2021 --> Jun 2020 | Trial primary completion date: Jan 2021 --> Oct 2019
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Enrollment open:  Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov) -  Apr 28, 2020   
    P3,  N=180, Recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P2 | Trial completion date: Jun 2021 --> Jun 2020 | Trial primary completion date: Jan 2021 --> Oct 2019 Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    Camrelizumab? (Twitter) -  Apr 27, 2020   
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma (clinicaltrials.gov) -  Apr 27, 2020   
    P=N/A,  N=270, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Aug 2020 | Trial primary completion date: Jan 2019 --> Aug 2020
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Enrollment open, Trial initiation date, Real-world evidence, Real-world:  HR-BLTN-016: Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer (clinicaltrials.gov) -  Apr 23, 2020   
    P=N/A,  N=3000, Recruiting, 
    The combination use could achieve good efficacy and prolong patients' PFS time; however, apatinib also reduced the patients' quality of life and enhanced the nutrition risk and adverse drug reactions. Not yet recruiting --> Recruiting | Initiation date: Nov 2019 --> Feb 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial primary completion date:  Camrelizumab Combined With Apatinib for Recurrent Resistant GTN (clinicaltrials.gov) -  Apr 20, 2020   
    P2,  N=20, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2020 --> Aug 2021
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, MSI-H, dMMR:  A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (clinicaltrials.gov) -  Apr 19, 2020   
    P2,  N=20, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2020 --> Aug 2021 Not yet recruiting --> Recruiting | N=70 --> 20 | Trial completion date: Jan 2025 --> Dec 2022 | Initiation date: Jan 2020 --> Apr 2020 | Trial primary completion date: Jan 2022 --> Apr 2022
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion date, Trial primary completion date:  Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer (clinicaltrials.gov) -  Apr 15, 2020   
    P2,  N=120, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Oct 2020
  • ||||||||||  VT-1598 / Mycovia Pharma, otesaconazole (VT-1161) / Mycovia Pharma, fluconazole / Generic mfg.
    Journal:  In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. (Pubmed Central) -  Apr 14, 2020   
    To evaluate their in vitro activities compared to other azoles, MICs were determined by Clinical and Laboratory Standards Institute (CLSI) method for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole, and posaconazole against 68 C...VT-1161 MICs were elevated compared to the control strain SC5314 for hyperactive Tac1 strains and two strains with Erg11 substitutions (Y132F and Y132F&K143R), but showed activity against hyperactive Mrr1 and Upc2 strains. While mutations affecting Erg3 activity appear to greatly reduce susceptibility to VT-1161 and VT-1598, the elevated MICs of both tetrazoles for four isolates could not be explained by known azole resistance mechanisms, suggesting the presence of undescribed resistance mechanisms to triazole- and tetrazole-based sterol demethylase inhibitors.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    New P2 trial:  A Phase II Study in Patients With Alopecia Areata (clinicaltrials.gov) -  Apr 14, 2020   
    P2,  N=80, Not yet recruiting, 
  • ||||||||||  ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers. (clinicaltrials.gov) -  Apr 13, 2020   
    P1,  N=6, Completed, 
    This phase 2 data warrant further clinical studies of camrelizumab plus apatinib in SCLC. Not yet recruiting --> Completed | Trial completion date: Aug 2020 --> Apr 2020 | Trial primary completion date: Aug 2020 --> Apr 2020